Advanced search
Publication Cover
Current Medical Research and Opinion Volume 35, 2019 - Issue sup3: Management of Patients with Heart Failure: Italian "Field Practice" Experience on Sacubitril/Valsartan
Submit an article Journal homepage
339
Views
2
CrossRef citations to date
0
Altmetric
Cardiovascular

Sacubitril/valsartan treatment improved the clinical outcome and reduced the hospitalization rate in three patients with chronic heart failure: a case series

Donatella SeveriniHeart Failure Ambulatory, Cardiology Unit, Hospital Città Di Castello, Città Di Castello, ItalyCorrespondence[email protected]
&
Kwame MboumiHeart Failure Ambulatory, Cardiology Unit, Hospital Città Di Castello, Città Di Castello, Italy
Pages 7-11 | Received 15 Oct 2018, Accepted 13 Mar 2019, Published online: 07 May 2019

References

  • Langenickel T, Dole W. Angiotensin receptor–neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discovery Today Ther Strategies. 2012;9:e131–e139.
  • McMurray J, Packer M, Desai A, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
  • Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.
  • Fruhwald S, Pollesello P, Fruhwald F. Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerations. Expert Rev Cardiovasc Ther. 2016;14:1335–1347.
  • Steinberg L, White M, Arvanitis J, et al. Approach to advanced heart failure at the end of life. Can Fam Physician. 2017;63:674–680.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.